August 2013: Nimotuzumab in MOGA Australia
Medical Oncology Group of Australia
Similar Posts
New Marketing Authorization Approval in The Philippines for new indication of locally advanced unresectable or metastatic pancreatic cancer.
ByInnokeysOn 18 Sep 2020, Philippines FDA approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for nimotuzumab. This…
Webinar – Current Update on Nasopharyngeal Carcinoma
ByInnokeysSpeakers: 1. dr. Kartika Widayati, Sp.PD-KHOM from Gadjah Mada University, Indonesia 2. dr. Susanna Hilda Hutajulu, Ph.D., SpPD-KHOM from RSUP Dr. Sardjito,…
Patent Pending for “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in numerous countries
ByInnokeysApplication for patents with the title of “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” are…
Update on Laryngeal Cancer
ByInnokeysSpeakers: 1. dr. Denny Satria Utama, Sp.T.H.T.L(K)., M.Si Med., FICS from Charitas Hospital Indonesia 2. Dr. dr. Fauziah Fardizza, Sp.T.H.T.K.L(K), FICS from…
Webinar – The Role of Nimotuzumab in the Treatment of Head and Neck and Nasopharyngeal Cancer
ByInnokeysThis webinar was conducted on May 28th, 2022 discussing the role of Nimotuzumab in the treatment of locally advanced squamous cell…
May 2015 : Innokeys Pte Ltd at Asia Biotech Invest 2015
ByInnokeysKowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies….